Heart ‘omics’ in AGEing (HOMAGE): design, research objectives and characteristics of the common database by Jacobs, L et al.
Available online at www.jbr-pub.org
Open Access at PubMed Central
The Journal of Biomedical Research, 2014, 28(5):349-359
Research Paper
Heart ‘omics’ in AGEing (HOMAGE): design, research objectives and
characteristics of the common database
Lotte Jacobsa, Lutgarde Thijsa, Yu Jina, Faiez Zannadb, Alexandre Mebazaac, Philippe Rouetd,
Florence Pinete, Christophe Bauterse, Burkert Pieskef, Andreas Tomaschitzf, Mamas Mamasg, Javier Diezh,
Kenneth McDonaldi, John G F Clelandj, Hans-Peter Brunner-La Roccak, Stephane Heymansl,
Roberto Latinim, Serge Massonm, Peter Severn, Christian Delleso, Stuart Pocockp, Timothy Collierp,
Tatiana Kuznetsovaa, Jan A Staessena,*. On behalf of the Heart ‘omics’ in AGEing (HOMAGE) investigators
a
Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of
Cardiovascular Sciences, University of Leuven, Leuven, Belgium;
bCentre d9 Investigation Clinique Pierre Drouin and U 961, Hypertension and Heart Failure Unit, Institut Lourrain du Coeur et
des Vaisseaux, Inserm, Nancy, France;
c
Department of Anesthesiology and Critical Care Medicine, InsermUMR-S942, Hoˆpital Lariboisie`re, Universite´ Paris Diderot,
Paris, France;
dEquipe obe´site´ et insuffisance cardiaque, Universite´ UPS, Inserm I2MC, UMR 1048, Toulouse, France;
e
Inserm, U744, CHRU, Lille, France;
f
Department of Cardiology, Medical University Graz, Austria;
g
Cardiovascular Institute, University of Manchester, Manchester, UK;
h
Division of Cardiovascular Sciences, Foundation for Applied Medical Research, University of Navarra, Pamplona, Spain;
i
Heart Failure Unit, St Vincent9 s University Hospital, University College Dublin, Dublin, Ireland;
j
Department of Cardiology, University of Hull, UK;
k
Department of Cardiology, Maastricht University Medical Centre, Netherlands;
l
Center for Heart Failure Research, Department of Cardiology, Maastricht University, Netherlands;
m
Department of Cardiovascular Research, IRCCS - Istituto di Ricerche Farmacologiche ‘‘Mario Negri’’, Milan, Italy;
n
International Center for Circulatory Health, Imperial College London, UK;
o
Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Center, University of Glasgow,
Glasgow, UK;
pLondon School of Hygiene and Tropical Medicine, London, UK.
Received 08 March 2014, Revised 31 March 2014, Accepted 24 June 2014, Epub 31 July 2014
Abstract
Heart failure is common in older people and its prevalence is increasing. The Heart ‘omics’ in AGEing
(HOMAGE) project aims to provide a biomarker approach that will improve the early diagnosis of heart failure.
A large clinical database, based on (1) prospective population studies or (2) cross-sectional, prospective studies
or randomized controlled trials (RCTs) of patients at risk for or with overt cardiovascular disease will be constructed
to determine most promising ‘omics’-based biomarkers to identify the risk of developing heart failure and/or
comorbidities. Population studies, patient cohorts and RCTs are eligible for inclusion in the common database,
if they received ethical approval to obtain and share data and have baseline information on cardiovascular risk fac-
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tors. Currently, the HOMAGE database includes 43,065 subjects, from 20 studies in eight European countries,
including healthy subjects from three population studies in France, Belgium and Italy (n 5 7,124), patients with
heart failure (n 5 4,312) from four cohorts in the UK, Spain and Switzerland and patients at high risk for cardi-
ovascular disease (n 5 31,629) in 13 cohorts. It is anticipated that more partners will join the consortium and
enlarge the pooled data. This large merged database will be a useful resource with which to identify candidate bio-
markers that play a role in the mechanism underlying the onset and progression of heart failure.
Keywords: left ventricle, heart failure, heart failure with reduced ejection fraction, heart failure with preserved
ejection fraction, population science, morbidity, mortality
INTRODUCTION
Heart failure is a progressive disease and is generally
preceded by asymptomatic structural and functional
changes in the heart. It further evolves into clinically
overt heart failure, disability and death
[1,2]
. The prognosis
of heart failure remains poor
[3]
and the 5-year mortality
rate of symptomatic heart failure is about 60%
[4-6]
.
Heart failure is a major public health concern with a
prevalence of about 1-2% of the adult population in
developed countries. It is a common disease in older
people (> 10% among persons > 75 years) and its pre-
valence is increasing as more people survive into old
age
[4,7]
. Heart failure is the single most common cause
for hospital admission (5% of all medical and geriatric
admissions) in people aged over 65 years
[4,8]
. Further-
more, it is complicated by many other medical problems
common in older people, such as renal dysfunction, pul-
monary disease, depression, cognitive decline, cerebro-
vascular disease and diabetes mellitus
[4,7]
.
The diagnosis of heart failure can be difficult, espe-
cially in the early stages, since many of the symptoms
and signs of heart failure are non-specific and thus do
not discriminate between heart failure and other pro-
blems
[9-11]
. Echocardiography is the most useful test
in patients with suspected heart failure
[12]
. However,
echocardiography is poorly suited for large scale rou-
tine screening. Plasma concentrations of natriuretic
peptides are better suited as screening tool than echo-
cardiography but their diagnostic accuracy is insuffi-
cient in detecting early cardiac dysfunction and they
provide little information on etiology
[13]
.
The availability of effective large-scale screening
tools for the identification of patients at risk of heart
failure (predictive markers) or at an early stage of heart
failure (diagnostic markers) is a major unmet clinical
need. The concept of the Heart ‘omics’ in AGEing
(HOMAGE) project, an EU FP7 program led by
Faiez Zannad (University of Lorraine, Nancy, France,
www.homage-hf.eu) is to identify ‘omics’-based bio-
markers that can detect pathological processes predic-
tive of the development of heart failure to allow early
therapeutic interventions for preventing heart failure.
The first step in this process is to develop a large data-
base of existing cohorts, including healthy individuals,
persons at risk of developing heart failure and patients
with heart failure. This database will be used to iden-
tify and validate the predictive value of ‘omics’-based
biomarkers in the progression of heart failure.
MATERIALS AND METHODS
Selection of studies
Eligible studies include population studies, patient
cohorts and randomized controlled trials (RCTs). The
studies should have received ethical approval to obtain
and share data, have baseline information on cardiovas-
cular risk factors and subsequent follow-up reports of
fatal and non-fatal outcomes, including heart failure.
Fourteen partners (Supplementary Table 1, avail-
able online) involved in the HOMAGE-consortium
contributed data from completed and ongoing studies.
Supplementary table 2 (available online) gives a
description of the work and work packages9 leaders
involved in HOMAGE.
For database management and statistical analyses,
SAS software version 9.3 (SAS Institute, Cary, NC,
USA) will be used.
Data collection
The HOMAGE database is constructed and main-
tained at the Studies Coordinating Centre in Leuven,
Belgium. By sending their data, the contributing part-
ner confirmed that their study complies with good
clinical practice (Helsinki Declaration), all participants
provided written informed consent and the study con-
formed to national regulations on clinical research in
humans and privacy at the time of its conduct. Each
investigator received summary statistics of his cohort,
after integration of the data into the common database,
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to ensure that correct information is incorporated. The
database will be held in strict confidence and will not
be used in any publication without the permission of
the investigators who have contributed their data.
Data requested from each contributing partner
includes baseline characteristics of each participant,
anthropometrics, previous medical history and medi-
cation use, routine hematological and biochemical
measurements, ECG data and echocardiographic vari-
ables. If available, information on already measured
biomarkers related to left ventricular dysfunction and
heart failure is included. For cohorts where follow-up
is still ongoing and that do not have outcome informa-
tion available at this moment, the database will be
updated at regular time points.
At the start of the project, each contributing partner
provided a detailed data dictionary that lists all vari-
ables made available, describing the variables9 names,
formats, labels and coding systems used.
Definition of events
Within the HOMAGE consortium an endpoint adju-
dication committee is established to agree on defini-
tions and criteria to classify clinical events and
phenotypes, in particular heart failure events, left ven-
tricular dysfunction, hypertension, diabetes, atrial
fibrillation, chronic obstructive pulmonary disease,
coronary, cerebrovascular and chronic kidney disease.
This committee will retrospectively assess the quality
of the endpoint adjudication of the available studies
incorporated in the common database
Research objectives
The main goal of the HOMAGE project is to provide
a novel set of ‘omics’ based biomarkers that will
greatly improve the detection of patients at risk of
developing heart failure, improve the accuracy of
diagnosis and identify patient subsets based on
mechanistic phenotypes with a greater likelihood of
response to targeted preventive therapies. We therefore
collected data from well-phenotyped cohorts, that
include both healthy persons and patients at risk of
developing heart failure, or with overt heart failure.
The diversity of the populations in terms of age, geo-
graphy and presence or absence of underlying diseases
will provide unique information on the determinants
and utility of candidate biomarkers.
First, we will validate the ability of distinct ‘omics’
biomarkers to predict the development of heart failure.
Therefore, cases, persons who developed heart failure,
and corresponding controls will be defined within the
available cohorts.
Other analyses related to information available in the
common database can be proposed by each investigator
of the HOMAGE consortium and will first be reviewed
by the HOMAGE steering committee in terms of the
research question and statistical soundness.
RESULTS
Currently, the HOMAGE database includes baseline
information of 20 existing cohorts consisting of a total of
43065 subjects from eight European countries (Fig. 1).
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Fig. 1 Overview of studies included in the HOMAGE database
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Of these 20 cohorts, three studies are population studies
(Table 1). Thirteen cohorts (Table 2 and 3) consist of
data from patients with cardiovascular risk and four stu-
dies include patients with (suspected) heart failure
(Table 4). Information on outcome, if currently avail-
able, is given in Table 5. Inclusion of new studies
and regular updates of existing cohorts on follow-up of
the subjects and on information of morbidity andmortal-
ity is planned.
Population cohorts
Description
The STANISLAS cohort is a family cohort consist-
ing of 4,295 healthy participants (1,006 families). The
participants were identified from the files of the State
Health Insurance Fund and invited to the Center for
Preventive Medicine of Vandoeuvre-le`s-Nancy (east-
ern France). The first visit was scheduled between
1993-1995. After the initial examination, participants
have been followed up 3 times every 5 years
[14,15]
.
The second population cohort is a large-scale
family-based study on the genetic epidemiology
of cardiovascular phenotypes, the FLEmish study
on Environment, Genes and Health Outcome
(FLEMENGHO). Recruitment started in 1985 through
1999, in a random sample of households living in a
geographically defined area of Northern Belgium
[16,17]
.
From 2005 until 2010, 1,208 former participants were
invited for a follow-up examination at the field center,
including echocardiography. 828 participants renewed
their informed consent and are included in the
HOMAGE database. Follow-up of these participants
is still ongoing.
A third population-based study is the PREDICTOR
cohort. From 2007 to 2010, a sample of 2001 elderly
(aged 65-84 years) residents of the Lazio region in cen-
Table 1 Baseline characteristics of population cohorts
Healthy subjects STANISLAS FLEMENGHO PREDICTOR
Number of patients 4295 828 2001
Women, No. (%) 2138 (50) 421 (51) 967 (48)
Age, years 27¡14 51¡16 73¡5
Body mass index, kg/m2 21.9¡4.4 26.6¡4.4 26.5¡4.2
Weight, kg 58.6¡17.7 75.8¡14.5 72.9¡13.5
Height, cm 162¡14 169¡9 166¡9
Smokers, No. (%) 793 (19) 169 (20) 259 (13)
Consume alcohol, No. (%) 1501 (35) 571 (69) 1177 (59)
Hypertension, No. (%) NA 333 (43) 1157 (58)
Diabetes mellitus, No. (%) NA 10 (1.2) 332 (17)
Heart failure, No. (%) NA 6 (0.72) 128 (6)
Systolic blood pressure, mmHg 119¡13 129¡17 139¡17
Diastolic blood pressure, mmHg 67¡13 80¡10 81¡9
Heart rate, beats per minute 70¡12 61¡10 71¡12
Cholesterol, mmol/L 5.2¡1.1 5.3¡0.97 5.3¡1.0
Glucose, mmol/L 5.0¡0.55 4.9¡0.81 5.8¡1.6
Hemoglobin, g/dL 14.2¡1.2 13.8¡1.3 14.0¡1.3
Red blood cell count, 1012 cells/L 4.8¡0.38 4.6¡0.41 4.7¡0.47
White blood cell count, 109 cells/L 7.0¡1.8 6.4¡1.8 6.4¡2.8
Platelets, 109 cells/L 284¡62 233¡59 232¡68
Creatinine, mmol/L 73.3¡15.3 84.2¡16.2 84.9¡23.7
BNP, pg/mL NA NA NA
NT-proBNP, pg/mL NA NA 92 (47-186)
Left ventricular mass, g NA 172¡49 166¡48
Left ventricular ejection fraction, % NA 69¡7 66¡7
Proportion with LVEF ,40% NA 2 (0.28) 28 (1.5)
Proportion with LVEF 40-50% NA 7 (0.98) 33 (1.8)
Proportion with LVEF .50% NA 702 (98.7) 1797 (96.7)
E/A ratio NA 1.3¡0.50 0.80¡0.25
Data are reported as number (%), mean¡SD or median (25th-75th percentile) for non-normally distributed variables.
NA: data not available within the cohort
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tral Italy, was randomly selected from the Regional
Health Registry
[18]
.
Characteristics
Baseline characteristics of these population cohorts,
including 7124 subjects, are given in Table 1. Overall
3526 (49%) are women and 1221 are smokers (17%),
with a mean (standard deviation [SD]) age of 43 (24)
years and a mean (SD) body mass index of 24 (5) kg/m
2
.
Cardiovascular risk patient cohorts and RCTs
Description
ADELAHYDE is a cross-sectional study of 378
hypertensive, elderly (. 65 years) patients, treated
with at least one antihypertensive agent and presenting
with subjective memory complaints. Patients were
recruited between 2003 and 2005 by local press adver-
tisements or referred by general practitioners from
an investigator network of the Inserm Clinical
Investigation Center, France
[19]
.
The R2C2 cohort on obesity and heart failure
risk factors aims to investigate the transition from
obesity to heart failure and consists of 169 subjects
with abdominal obesity, born or living in France for
at least 10 years, that had been recruited between
2006 and 2009
[20]
. No outcome information is avail-
able.
BIOMARCOEURS recruited 1,117 French patients
with a primary complaint of acute dyspnea at the
emergency department. Follow-up, by phone contact,
was performed after one year
[21]
.
The IBLOMAVED cohort includes 502 subjects,
born or living in France for at least 10 years, and was
designed to investigate biomarkers of asymptomatic left
ventricular dysfunction. The selected subjects are both
patients at risk of developing heart failure as well as
Table 2 Baseline characteristics of CV-risk patient cohorts
CV-risk patients ADEDLAHYDE R2C2 BIOMARCOEURS IBLOMAVED REVE GECOH HVC
Number of patients 378 169 1117 502 512 266 1880
Women, No. (%) 205 (54) 87 (51.5) 473 (42.3) 156 (31.1) 113 (22.1) 162 (60.9) 961 (51.1)
Age, years 70¡6 55¡6 71¡16 60¡13 58¡14 50¡17 58¡15
Body mass index, kg/m2 28.0¡4.3 28.8¡5.3 26.6¡6.2 27.0¡5.4 27.1¡4.7 28.7¡6.3 27.3¡5.4
Weight, kg 76.1¡14.0 80.7¡16.4 74.4¡18.3 77.2¡18.1 78.5¡15.1 82.9¡19.0 79.4¡17.4
Height, cm 165¡9 167¡9 167¡9 169¡9 170¡8 170¡9 170¡10
Smokers, No. (%) 30 (7.9) 24 (14) 261 (23) 67 (14) 238 (47) 29 (11) 362 (19)
Consume alcohol, No. (%) 258 (68) 125 (74) 112 (10) NA NA 114 (43) NA
Hypertension, No. (%) 378 (100) NA 614 (55) 227 (45) 209 (41) 269 (100) 784 (42)
Diabetes mellitus, No. (%) 40 (11) NA 291 (26) 100 (20) 111 (22) 25 (9) 211 (11)
Heart failure, No. (%) NA NA 361 (32) 332 (66) NA NA 53 (3)
Systolic blood pressure, mmHg 139¡18 125¡14 138¡30 124¡23 111¡16 154¡23 143¡24
Diastolic blood pressure, mmHg 74¡10 77¡9 79¡17 76¡14 64¡12 94¡14 83¡12
Heart rate, beats per minute 64¡10 63¡9 94¡25 72¡16 70¡13 71¡11.9 74¡14
Cholesterol, mmol/L 5.6¡0.89 5.7¡0.96 NA 4.4¡1.3 NA 5.2¡0.98 5.4¡2.0
Glucose, mmol/L 5.7¡1.5 5.1¡0.89 8.5¡4.8 NA NA 5.3¡1.4 6.0¡4.0
Hemoglobin, g/dL NA NA 12.6¡1.9 13.5¡1.8 NA 14.1¡1.2 14.2¡1.4
Red blood cell count, 1012 cells/L NA NA NA NA NA 4.8¡0.42 NA
White blood cell count, 109 cells/L NA NA 10.0¡6.4 7.5¡2.4 NA 6.3¡2.2 NA
Platelets, 109 cells/L NA NA NA NA NA 253¡65 NA
Creatinine, mmol/L NA 84.6¡11.9 116.2¡90.4 108.9¡66.8 NA 83.9¡53.2 88.7¡44.4
BNP, pg/mL NA NA 713 (211-1583) 493 (315-1750) NA NA NA
NT-proBNP, pg/mL NA NA NA NA NA 78 (40-167) 32 (10-130)
Left ventricular mass, g NA 162¡50 NA NA NA NA NA
Left ventricular ejection fraction, % NA 68¡7 45¡17 46¡20 49¡9 NA 61¡8
Proportion with LVEF ,40% NA 0 198 (37) 217 (45) 70 (14) NA 43 (3)
Proportion with LVEF 40-50% NA 0 91 (17) 60 (12) 193 (38) NA 54 (4)
Proportion with LVEF .50% NA 154 (100) 246 (46) 209 (43) 244 (48) NA 1167 (92)
E/A ratio NA 1.2¡0.33 NA NA NA NA 1.2¡3.3
Data are reported as number (%), mean¡SD or median (25th-75th) for non-normally distributed variables.
NA: data not available within the cohort
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patients with heart failure. IBLOMAVED is a cross-
sectional study, with no follow-up data
[22]
.
Together, REVE-1 (n5 266) and REVE-2 (n5 246)
include 512 patients with anterior acute myocardial
infarction and were designed to study left ventricular
remodelling after myocardial infarction. Recruitment
took place in Region Nord-Pas-de-Calais, France
between 2002 and 2004 for REVE-1
[23]
and between
2006 and 2008 for REVE-2
[24]
. At this moment, all
patients have been followed-up two times at 3 months
and at 12 months after the baseline examination, during
hospitalization.
The Graz Endocrine Causes of Hypertension
(GECOH) study is a single center study in patients
referred for endocrine hypertension to the outpatient
clinic of a tertiary care center
[25]
. Currently, baseline
data from 266 Austrian patients are available.
The HVC database consists at this moment of 1,880
patients referred to the cardiovascular outpatient clinic
of Maastricht University, Netherlands, for a consulta-
tion by a cardiologist for the first time. Both baseline
and follow-up information is available.
The left ventricular Dysfunction in DIAbetes (DYDA)
cohort assessed the prevalence of left ventricular systolic
or diastolic dysfunction in 937 patients with diabetes.
Patients were recruited from 37 Italian diabetes referral
centers from 2006 until 2008. Follow-up data up until
24 months are available
[26]
.
EPATH is a single-center, double-blind, placebo
controlled, randomized, parallel group trial in patients
with primary hyperparathyroidism, who are rando-
mized to receive eplerenone or placebo
[27]
. This trial
is ongoing and at this moment baseline information
of 40 subjects is available.
Table 3 Baseline characteristics of CV-risk patient cohorts (continuation of Table 2 )
CV-risk patients DYDA EPATH STYRIAN VITD STOP-HF ASCOT PROSPER
No. of patients 937 40 286 481 19257 5804
Women, No. (%) 358 (38) 32 (80.0) 136 (48) 264 (55) 4515 (24) 3000 (52)
Age, years 62¡8 69¡10 60¡11 67¡10 63¡9 75¡3
Body mass index, kg/m2 28.6¡4.4 28.7¡6.4 29.5¡4.8 30.3¡4.8 28.7¡4.6 26.8¡4.2
Weight, kg 79.5¡14.6 75.0¡16.9 84.7¡17.6 85.4¡16.3 84.6¡15.5 73.4¡13.4
Height, cm 167¡10 162¡9 169¡9 168¡10 172¡9 165¡9
Smokers, No. (%) 179 (19) 4 (10) 42 (14) 36 (8) 6277 (33) 1558 (27)
Consume alcohol, No. (%) NA 19 (48) 239 (84) 298 (62) 14294 (74) 3228 (56)
Hypertension, No. (%) 602 (64) 24 (60) 286 (100) NA 19257 (100) 3592 (62)
Diabetes mellitus, No. (%) 937 (100) 3 (8) 58 (20) 145 (30) 5145 (27) 623 (11)
Heart failure, No. (%) 0 4 (10) NA 0 0 0
Systolic blood pressure, mmHg 137¡15 143¡20 141¡18 132¡17 164¡18 155¡22
Diastolic blood pressure, mmHg 80¡8 87¡11 87¡12 82¡11 95¡10 84¡12
Heart rate, beats per minute 73¡10 66¡11 63¡10 70¡12 72¡13 NA
Cholesterol, mmol/L 5.0¡0.95 5.1¡1.1 5.2¡1.2 4.7¡0.94 5.9¡1.1 5.7¡0.91
Glucose, mmol/L 8.3¡2.3 5.5¡1.2 6.0¡1.9 7.1¡2.7 6.2¡2.1 NA
Hemoglobin, g/dL NA 13.7¡1.4 14.2¡1.3 NA NA NA
Red blood cell count, 1012 cells/L NA 4.6¡0.44 4.8¡0.40 NA NA NA
White blood cell count, 109 cells/L NA 6.1¡1.8 5.9¡1.6 NA NA NA
Platelets, 109 cells/L NA 225¡64 234¡61 NA NA NA
Creatinine, mmol/L 80.3¡23.7 73.5¡15.8 82.7¡23.6 NA 98.7¡16.8 NA
BNP, pg/mL NA NA NA 24 (12-52) NA NA
NT-proBNP, pg/mL 36 (16-69) 112 (51-186) 85 (45-159) NA NA NA
Left ventricular mass, g 172¡42 NA NA 178¡49 NA NA
Left ventricular ejection fraction, % 61¡5 64¡9 NA 67¡8 NA NA
Proportion with LVEF ,40% 3 (0.44) 1 (3) NA 2 (0.42) NA NA
Proportion with LVEF 40-50% 16 (2) 1 (3) NA 9 (2) NA NA
Proportion with LVEF .50% 669 (97) 34 (94) NA 465 (98) NA NA
E/A ratio 0.89¡0.24 0.95¡0.38 NA 0.85¡0.27 NA NA
Data are reported as number (%), mean¡SD or median (25th-75th) for non-normally distributed variables.
NA: data not available within the cohort
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The Styrian Vitamin D Hypertension trial is a ran-
domized double-blind placebo controlled trial with
the main aim to study the effects of vitamin D supple-
mentation on systolic blood pressure in vitamin D
deficient hypertensive patients recruited from Austria.
The trial is ongoing and currently baseline data from
286 subjects are available.
The St Vincent9 s Screening to Prevent Heart Failure
Study (STOP-HF) is a parallel-group randomized trial
involving 1,374 participants with cardiovascular risk
factors recruited from 39 primary care practices in
Ireland between 2005 and 2009 and followed up until
2011, with a mean follow-up time of 4.2 years
[28]
.
Patients were randomly assigned to receive usual pri-
mary care or screening with brain natriuretic peptide
(BNP) testing (n 5 697). Baseline and follow-up
information of 481 of the 1,374 subjects is now
included in the common database.
Patients included in the multicenter, prospective,
randomized Anglo-Scandinavian Cardiac Outcomes
Trial (ASCOT) are also included in the common data-
base
[29,30]
. The 19,257 hypertensive patients were
recruited between 1998 and 2000, and randomized to
amlodipine adding perindopril as required to reach
blood-pressure targets (amlodipine-based regimen) or
atenolol adding bendroflumethiazide and potassium
as required (atenolol-based regimen). The median fol-
low-up was 5.5 years.
The PROspective study of pravastatin in the elderly
at risk (PROSPER) cohort contributes 5804 elderly
subjects (> 70 years) with vascular disease or at high
risk of developing vascular disease. This double-blind,
randomized, placebo-controlled trial was designed to
examine the hypothesis that pravastatin, at a dose of
40 mg/day, would reduce the risk of cardiovascular
and cerebrovascular events in elderly subjects.
Table 4 Baseline characteristics of heart failure patient cohorts
Heart failure patients HFGR LEITZARAN HULL LIFELAB TIME-CHF
Number of patients 218 233 3239 622
Women, No. (%) 59 (27) 109 (46) 1068 (33) 253 (40.7)
Age, years 67¡13 74¡9 71¡11 77¡8
Body mass index, kg/m2 28.7¡5.6 31.3¡5.3 29.2¡6.0 25.6¡4.4
Weight, kg 82.6¡19.2 79.4¡16.3 82.4¡19.3 72.0¡14.2
Height, cm 171¡10 159¡10 168¡10 167¡9
Smokers, No. (%) NA NA 300 (9) 74 (12)
Consume alcohol, No. (%) NA 18 (8) 1179 (36) NA
Hypertension, No. (%) 92 (42) 233 (100) 1115 (35) 462 (74)
Diabetes mellitus, No. (%) 75 (34) 0 (0) 784 (24) 222 (36)
Heart failure, No. (%) 218 (100) 233 (100) 2306 (71) 622 (100)
Systolic blood pressure, mmHg 121¡22 148¡24 137¡25 122¡20
Diastolic blood pressure, mmHg 68¡11 85¡13 79¡14 72¡12
Heart rate, beats per minute 72¡14 79¡20 74¡17 76¡14
Cholesterol, mmol/L 4.0¡1.2 5.2¡1.8 4.4¡1.3 4.2¡1.1
Glucose, mmol/L 8.0¡3.3 6.0¡1.7 6.8¡2.9 6.7¡2.4
Hemoglobin, g/dL 13.0¡1.9 14.0¡1.5 13.3¡3.7 13.1¡1.8
Red blood cell count, 1012 cells/L NA 4.6¡0.47 NA 4.3¡0.60
White blood cell count, 109 cells/L 7.7¡2.7 7.0¡1.8 7.6¡2.8 7.8¡4.9
Platelets, 109 cells/L 223¡71 223¡58 242¡95 NA
Creatinine, mmol/L 111.2¡34.8 96.4¡33.8 105.7¡50.6 115.9¡38.4
BNP, pg/mL NA NA NA NA
NT-proBNP, pg/mL NA NA 880 (279-2088) 3836 (1919-6895)
Left ventricular mass, g NA 270.6¡115.8 271.6¡116.0 NA
Left ventricular ejection fraction, % 35¡12 55¡16 41¡14 35¡13
Proportion with LVEF ,40% 70 (65) 24 (17) 880 (51) 402 (65)
Proportion with LVEF 40-50% 20 (19) 21 (15) 360 (21) 108 (17)
Proportion with LVEF .50% 17 (16) 96 (68) 481 (28) 112 (18)
E/A ratio NA 0.90¡0.46 1.1¡0.85 NA
Data are reported as number (%), mean¡SD or median (25th-75th) for non-normally distributed data.
NA: data not available within the cohort
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Recruitment took place between 1997 and 1999, with a
median follow-up of 3.3 years
[31,32]
.
Characteristics
The baseline characteristics of these 31,629 patients
are given in Table 2 and 3. The thirteen cohorts (both
observational studies and RCTs) include 10,462
women and 9,107 smokers with a mean (SD) age of
65 (11) years and a mean (SD) body mass index of
28 (5) kg/m
2
. Twenty-four percent of the patients suffer
from diabetes mellitus, while 85 % report a history of
hypertension.
Heart failure patient cohorts and RCTs
Description
The Heart Failure Glucose Regulation (HFGR)
cohort consists of baseline data from 218 patients with
heart failure and left ventricular systolic dysfunction,
attending heart failure clinics in Manchester. Patients
are followed up every 12 months over a 5 year period.
As follow-up is still ongoing, no outcome information
is available at this moment.
LEITZARAN contributes data from 233 Spanish
patients with heart failure of hypertensive origin.
Currently, no follow-up information is available.
The HULL LIFELAB cohort includes 3,239 patients
with suspected heart failure. Both baseline and outcome
information are available within this cohort.
Data from The Trial of Intensified versus standard
Medical therapy in Elderly patients with Congestive
Heart Failure (TIME-CHF) were contributed to the
database
[33]
. TIME-CHF is a multicenter, randomized
trial conducted in 15 centers in Switzerland and
Germany. Patients aged 60 years or older with dyspnea
(New York Heart Classification NYHA class > II with
current therapy), a history of hospitalization for heart
failure within the last year, and an nt-proBNP level
of > 400 pg/mL (in patients younger than 75 years)
or a level of 800 pg/mL (in patients aged 75 years or
older) were eligible for inclusion. The study rando-
mized 499 symptomatic heart failure patients with a
left ventricular ejection fraction of # 45% to intensi-
fied, NT-proBNP-guided versus a standard, symp-
tom-guided therapy. Baseline data from 622 patients
are included in the common database (499 randomized
patients + additional 123 patients with a left ventricular
ejection fraction of . 45%).
Characteristics
Table 4 summarizes the baseline characteristics of
the 4,312 heart failure patients from these four studies,
with mean (SD) age of 72 (11) years, and with a pro-
portion of 1,376 (53%) patients with left ventricular
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ejection fraction below 40%. In HFGR, 25% of
patients were classified into NYHA class I, 51% to
class II, 23% to class III and 1% to class IV.
Fifty percent of patients in HULL LifeLab were
classified to NYHA class II, 28% to class III and 2%
to class IV. For TIME-CHF, 24% of the patients
belonged to NYHA class II, 62% to class III and
14% to class IV.
DISCUSSION
Our database already includes 43065 subjects, of
which more than half (51.6%) are older than 65 years
and about 20% are older than 75 years. The main goal
of the HOMAGE project is to provide a novel set of
‘omics’ based biomarkers that will greatly improve the
detection of patients at risk of developing heart failure,
improve the accuracy of diagnosis and identify patient
subsets based on mechanistic phenotypes with a greater
likelihood of response to targeted preventive therapies.
The first step in this process is the development of the
common database consisting of existing cohorts to vali-
date the most promising biomarkers for the prediction of
incident heart failure in elderly patients at risk of or with
asymptomatic left ventricular dysfunction. Furthermore,
the cohort will also provide epidemiological data from
a wide number of partner institutions across Europe
regarding the prevalence of comorbid conditions, treat-
ments and outcomes in patients with cardiovascular dis-
ease and at high risk for developing heart failure as well
as in patient with heart failure.
Most of the cohorts do not include patients with
overt heart failure stage C and D as defined by the
ACC/AHA working group.
34
Incident cases of heart
failure, either using the definition supplied for the
individual population and patient cohorts or using the
common criteria developed by the adjudication com-
mittee, will be compared with matched controls, also
selected from the included ‘healthy’ cohorts. This will
be used to identify one or more biomarker ‘footprints’
for new-onset heart failure. Further prospective valida-
tion of this biomarker profile will be done, on the one
hand, by identifying new cases of heart failure within
the available cohorts that continue to follow their
patients and, on the other hand, by setting up a new
trial in elderly patients at high risk of heart failure
investigating the safety and therapeutic response to
mineralocorticoid receptor antagonists according to
‘omics’-based biomarker profiles.
Treating hypertension is highly effective at delaying
the onset of and perhaps preventing heart failure in
older people
[35]
. However, not all antihypertensive
agents are similarly beneficial, but the number needed
to treat is rather high
[36,37]
. Other preventive therapies
targeting glycemic control and cholesterol have been
disappointing. Many patients with heart failure have
associated comorbidities such as hypertension, diabetes
mellitus, ischemic heart disease, atrial fibrillation,
chronic lung disease, renal dysfunction and anemia.
Stratification beyond such gross phenotypes using
‘omic’ technologies may help target therapeutic inter-
vention more safely and effectively.
Candidate ‘omics’-based biomarkers (Supplemen-
tary Table 3, available online) relevant to heart fail-
ure, processes of aging, inflammation, fibrosis or myo-
cyte damage and related to main comorbid conditions
of heart failure in elderly people have been selected
after a systematic search of relevant scientific and
patent databases after consulting experts within the
present HOMAGE consortium. All candidate biomar-
kers have passed the discovery and verification phase,
are published or patented by SMEs or academic
groups, including groups in the HOMAGE consortium
and are readily measurable by available techniques.
Emphasis is on validation of clinically useful biomar-
kers that can predict the risk of developing heart fail-
ure, help make an early diagnosis or help choose the
right treatment, at the right time for the right patient.
The consortium is also open for discovery of novel
markers, novel insights into pathophysiology and
identification of novel therapeutic targets.
Each investigator of the HOMAGE consortium can
propose analyses using the information available in
the common database that eventually could lead to the
discovery of new biomarkers, patents or publications.
In conclusion, HOMAGE has assembled a very
large set of international data and biological samples
focusing on patients at risk of, or with heart failure, that
will be an important platform for bio-marker discovery.
This research will increase understanding of the
mechanisms underlying the development and progres-
sion of heart failure. It will also focus attention on the
need to select, more precisely, treatments that are safe
and highly effective rather than the traditional cardio-
vascular approach that often relies on modest average
benefits, at a population level, that usually reflects the
net impact of a large benefit in a few and no effect or
harm in others. We should and can do better than this!
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Supplementary Table 1 Contributing HOMAGE investigators
Leuven, Belgium Kei Asayama, Yumei Gu, Asuza Hashimoto, Judita Knez, Yanping Liu, Thibault Petit, Fangfei We, Zhenyu Zhang
Inserm Nancy, France Adriano Burcheri-Curatolo, Daniele Dobre, Nicoloas Girerd, Ludovic Merckle, Anne Pizard, Faiez Zannad
Inserm Paris, France Oksana Kovalska, Damien Logeart, Saı¨d Laribi, Marie-France Seronde, Ali Tahraoui, Nicolas Deye, Jean-
Marie Launay, Philippe Manivet, Remi Bonnet, Be´atrice Lemosquet, Nicolas Segal, Patrick Plaisance, Malha
Sadoune, Nicolas Vodovar, Alain Cohen Solal
Inserm Toulouse, France Franck Desmoulin, Manon Barutaut, Michel Galinier, Matthieu Berry, Celine Caubere, Maria Evaristi,
Pauline Fournier, Annie Turkieh, Fatima Smih
Inserm Lille, CHRU, Lille, France Nicolas Lamblin, Marie Fertin, Gilles Lemesle
Graz, Austria Andreas Meinitzer, Caterina Colantonio, Albrecht Schmidt, Elisabeth Kraigher-Krainer, Rolf Wachter, Frank
Edelmann
Manchester, UK Ludwig Neyses, Christi Deaton, Martin Yuille, Muhammad Khan, Robert Oliver
Pamplona, Spain Arantxa Gonza´lez, Begona Lopez, Ramon Querejeta, Elena Zubillaga
Dublin, Ireland Mark Ledwidge, Eoin O9 Connell, Chris Watson, Kenneth McDonald
Hull, UK Andrew Clark, Rachel Nicholls, Syed Kazmi
Maastricht, Netherlands Mark Hazebroek, Sema Bektas, Sandra Sanders-van Wijk, Kimberly Everaerts, Desiree Rutten, Matthias E.
Pfisterer (Basle Switzerland), TIME-CHF investigators
Milan, Italy Nera Agabiti, Alessandro Boccanelli, Marco Comaschi, Marina Davoli, Carlo B. Giorda, Roberto Latini,
Donata Lucci, Aldo P. Maggioni, Serge Masson, Flavia Mayer, Gian Francesco Mureddu
London, UK Neil Poulter, Bjorn Dahlof, Eoin O9 Brien
Glasgow, UK Naveed Sattar, Paul Welsh, Ian Ford (PROSPER), Wouter Jukema (Eindhoven, The Netherlands;
PROSPER), Brendan Buckley (Cork, Ireland; PROSPER)
Supplementary Table 2 Work description and work package leaders within the HOMAGE consortium
Work package title Principal investigator Institute
General coordination Faiez Zannad Inserm, France
Coordination of clinical studies and centres Ste´phanie Grojean Fondation Transplantation EDDH, France
Cohorts studies for diagnosis and risk prediction Faiez Zannad Inserm, France
Prediction of therapeutic response John Cleland University of Hull, UK
Biobanking and bio-informatics Stephane Heymans Maastricht University, Netherlands
Bio-assay Jim Curry Randox Testing Service, UK
Data management and statistical analysis Jan A. Staessen / Stuart Pocock University of Leuven, Belgium / London
School of Hygiene, UK
Industrial application, regulatory consultation and
market research
Yigal Pinto / Joost Leenders ACS Biomarker, Netherlands
Dissemination and changing clinical practices Faiez Zannad / Patricia Joseph-Mathieu Inserm, France / Inserm Transfert, France
Management and coordination Patricia Joseph-Mathieu Inserm-Transfert SA, France
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Supplementary Table 3 List of candidate proteomics-based biomarkers
Domain Candidate marker Processes Biofluid (volume needed)
miRNA-omics miR-208, -499, -423-5p, -221, -132, -21, -126, -18 &- 19 and -22 & -24 F, I, M, A Serum/plasma (0.5 mL)
Transcriptomics Neutrophil gelatinase-associated lipocalin (NGAL) I, M Serum/plasma (0.1 mL)
Anaplastic lymphoma receptor tyrosine kinase (ALK) M PBMC (5 mL for all)
Nerve growth factor beta (NGFb) M
F-box and WD repeat domain containing 7 (FBXW7) M
Ferrochelatase (FECH) M
CX3C chemokine receptor 1 (CX3CR1) I, M PBMC (1 mL for all)
Chemokine (C-C motif) receptor 2 (CCR2) I, M
CD28 F, I, M, A PBMC (2 mL for all)
CD69 F, I, M, A
Lymphocyte-specific protein tyrosine kinase (LCK) F, I, M, A
Heme oxygenase 1 (HMOX1) F, I, M, A
TNF receptor superfamily member 1A (TNFRSF1A) F, I, M, A
B-cell CLL lymphoma 2 (BCL2) F, I, M, A
Caspase 8 F, I, M, A
Chemokine (C-C motif) ligand 5 (CCL5) F, I, M, A
DNA damage-inducible transcript 3 (DDIT3) F, I, M, A
Early growth response 3 (EGR3) F, I, M, A
IL10RB F, I, M, A
IL1R2 F, I, M, A
Serpin peptidase inhibitor B2 (SERPINB2) F, I, M, A
TIMP1 F, I, M, A
Thrombospondin 2 F Serum/plasma (0.2 mL)
Glycoprotein-Nmb F
COL4A1 F, M Serum/plasma (0.2 mL)
Pentraxin F, M
Proteomics Senescence associated secreted proteins including IL-8, GRO-a,
GM-CSF, hsIL6 and MCP1
I, A Serum/plasma (0.5 mL)
Phosphorylated troponin T M Serum/plasma (0.1 mL)
Quiescin-sulfhydryl oxidase 1 (QSOX-1 M Serum/plasma (0.2 mL)
CD146 M
Soluble TWEAK (sTWEAK) I, M Serum/plasma (0.1 mL)
Cathelicidin-related antimicrobial protein (CRAMP), F, A Serum/plasma (0.5 mL)
Stathmin F, A
Elongation factor 1 alpha (EF-1) F, A
Chitinase 3-like protein 3 F, A
243 urinary peptides F, I, M Urine (1.5 mL)
Metabolomics a-Ketoglutarate M Serum (0.25 mL)
Pseudouridine M
c-Glutamyl leucine and valine F, I, M
Asymmetric and symmetric dimethylarginin F, I, M
5-Hydroxy-tryptamine (Serotonin) M
Amino acids and derivates F, I, M, A Serum/plasma (20 mL)
Biogenic amines F, I, M, A
Acylcarnitines M, A
Sphingolipids F, I, M
Glycerolphospholipids F, I, M
The processes, in which proposed biomarkers are involved in, include ageing (A), inflammation (I), fibrosis (F) myocyte damage (M) or combinations.
PBMC: peripheral blood mononuclear cell.
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